![]() |
市场调查报告书
商品编码
1470905
止血剂市场:按类型、配方和应用分类 - 2024-2030 年全球预测Hemostats Market by Type (Collagen-Based Hemostats, Combination Hemostats, Gelatin-Based Hemostats), Formulation (Matrix & Gel Hemostats, Powder Hemostats, Sheet & Pad Hemostats), Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年止血剂市场规模为32.3亿美元,预计2024年将达34.2亿美元,2030年将达47.5亿美元,复合年增长率为5.65%。
止血剂是各种医疗设备和产品,旨在控制、预防和止血手术和创伤过程中的出血。这些医疗设备在控制出血、促进组织正常癒合、同时降低併发症风险方面发挥重要作用。止血剂在许多外科专业中都有应用,包括心血管外科、一般外科、整形外科、神经外科、妇科外科和牙科外科。与人口老化相关的慢性病的增加增加了对需要有效止血解决方案的手术的需求,导致各种止血剂的使用增加。此外,人们对微创手术的日益青睐,以及政府机构和医疗机构为改善手术基础设施而增加的投资,也增加了止血剂的使用。与开发创新产品相关的高昂研发成本以及止血剂污染的高风险正在阻碍市场成长。市场供应商不断开拓生物相容性止血剂,提供有效的出血控制,同时最大限度地减少副作用,预计将创造市场成长机会。
主要市场统计 | |
---|---|
基准年[2023] | 32.3亿美元 |
预测年份 [2024] | 34.2亿美元 |
预测年份 [2030] | 47.5亿美元 |
复合年增长率(%) | 5.65% |
由于减少型出血的有效性提高,合併止血剂的使用增加
胶原蛋白止血剂源自精製的胶原蛋白,以其优异的生物相容性和透过引发血小板凝集促进血栓形成的能力而闻名。这些止血剂是涉及软组织和脆弱结构的手术的首选,例如神经外科手术和眼科手术。复方止血剂由两种或多种活性剂组成,它们协同作用以增强止血功效。一般来说,产品结合了胶原蛋白、明胶和凝血酶等止血剂的优点。由于复合止血剂在减少复杂手术过程中出血併发症的有效性不断提高,因此对复合止血剂的需求不断增加。氧化再生纤维素止血剂是由植物来源的纤维素经过氧化再生过程製成的。它具有抗菌特性,透过在血管和周围组织之间形成物理屏障来有效控制出血。基于 ORC 的止血剂常用于牙科、胃肠道和妇科手术。凝血酶止血剂含有人类或牛凝血酶作为活性成分,可活化凝血连锁并迅速形成血栓。它对于控制传统技术无效或不切实际的出血特别有用,例如心血管手术或器官移植。胶原蛋白止血剂具有高度生物相容性,通常是精细手术的首选。联合止血剂由于协同效应而更加有效。明胶止血剂因其在危急情况下快速凝固血液的能力而受到重视。基于 ORC 的止血剂具有抗菌特性,并为控制出血创建物理屏障,而基于凝血酶的止血剂则激活凝血连锁并快速形成血栓。
粉末状止血剂在製定的外科手术过程中控制和预防出血的潜力越来越大。
基质止血剂和凝胶止血剂是生物相容性、可吸收的材料,可促进血栓快速形成。当在手术期间难以施加直接压力时,例如在微创手术中,这是优选的。粉状止血剂吸收出血组织中的液体并促进血小板聚集。易于使用,使其适用于各种外科手术,包括一般外科、整形外科、心血管外科和神经外科。止血片和止血垫片是柔性的生物可吸收材料,使其高度适应不规则的伤口表面。用于需要覆盖大面积且缝合困难的手术。海绵止血剂是一种高吸水性材料,易于成型为各种形状,适用于不规则的创腔。常用于牙科、口腔外科、神经外科、心血管外科等。基质和凝胶止血剂可在难以到达的区域快速形成凝块,而粉末止血剂则易于在外科专业中使用。海绵止血剂也为不规则的创腔提供优异的吸收性和成型性。
应用止血剂在心血管手术中的重要角色是防止出血,确保手术效果。
在心血管手术中,有大量的血液流经动脉和静脉,需要高效率的止血材料来防止出血。止血剂由于其快速作用和实现有效止血的能力而在这些手术中被广泛优选。在一般外科手术中,止血剂的使用在伤口处理和确保盲肠和疝气修復等手术期间尽量减少出血方面发挥重要作用。妇科手术通常需要在子宫切除术和子宫肌瘤切除术等精细手术中仔细控制出血。止血剂有效地减少粘连,同时在此类手术过程中提供充分的止血。止血剂是专门为满足这些需求而设计的,同时保留神经结构。关节重建和骨折融合术等整形外科手术需要强大的止血器来切割緻密的骨骼和结缔组织。在包括植皮和皮瓣重组的重组手术中,失血控制对于手术的成功至关重要。在这些情况下,首选止血剂,因为它们与多种组织相容,并且可以有效密封大伤口。与其他应用相比,心血管手术对先进止血剂的需求很高。
区域洞察
先进医疗设施的不断增加和外科手术数量的增加,特别是在美国、加拿大和巴西,正在推动美洲止血剂市场的成长。根据美国整形外科医师协会的数据,2022 年总合进行了 1,017,003 例需要使用止血剂的重组手术。加拿大、杜拜、新加坡、日本和英国医疗旅游的新兴趋势正在扩大微创手术的数量,并为止血剂市场形成一个平台。根据医疗旅游指数调查 (MTA),加拿大是首选旅游目的地之一,吸引了约 1,400 万名来自其他国家的美国人。医疗设备正在加强欧洲市场。由于医疗保健成本不断上升以及政府努力实现医疗保健基础设施现代化,中东和非洲地区提供了充满希望的成长机会。在沙乌地阿拉伯、阿拉伯联合大公国和南非等国家,随着外科手术数量的增加,对有效止血解决方案的需求正在迅速增加。此外,由于政府增加了扩大国内医疗设备製造的资金以及人们对微创手术的认识不断增强,印度、澳洲、中国和日本正在推动亚太地区的市场成长。
FPNV定位矩阵
FPNV定位矩阵对于评估止血剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对止血器市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.止血器市场的市场规模与预测是多少?
2.在止血剂市场预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.止血剂市场的技术趋势和法规结构是什么?
4.止血器市场主要厂商的市场占有率是多少?
5. 进入止血剂市场的适当形式和策略手段是什么?
[192 Pages Report] The Hemostats Market size was estimated at USD 3.23 billion in 2023 and expected to reach USD 3.42 billion in 2024, at a CAGR 5.65% to reach USD 4.75 billion by 2030.
The hemostats are a range of medical devices and products designed to control, prevent, and stop bleeding during surgical procedures and traumatic injuries. These devices play an important role in managing blood loss and facilitate proper tissue healing while reducing the risk of complications. Hemostats have applications in numerous surgical specialties, including cardiovascular surgery, general surgery, orthopedic surgery, neurosurgery, gynecologic surgery, and dental surgery. The growing occurrence of chronic diseases among an aging population drives the demand for surgeries that necessitate effective blood loss management solutions, consequently expanding the utilization of diverse hemostatic agents. Additionally, increasing inclination toward minimally invasive procedures with rising investments by government bodies and healthcare organizations to improve surgical infrastructure is raising the usage of hemostats. High R&D costs associated with developing breakthrough products and a high risk of contamination with hemostats hamper market growth. The increasing development of biologically compatible hemostats by market vendors that minimize adverse effects while providing effective bleeding control is expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.23 billion |
Estimated Year [2024] | USD 3.42 billion |
Forecast Year [2030] | USD 4.75 billion |
CAGR (%) | 5.65% |
Type: Expanding the use of combination hemostats owing to their enhanced effectiveness in minimizing bleeding
Collagen-based hemostats are derived from purified collagen; they are known for their excellent biocompatibility and ability to accelerate clot formation by initiating platelet aggregation. These hemostats are often preferred in surgeries involving soft tissues and delicate structures, such as neurosurgery and ophthalmic surgery. Combination hemostats consist of two or more active agents that work synergistically to enhance hemostatic efficacy. They typically combine the benefits of hemostats, such as collagen-based, gelatin-based, and thrombin-based products. The demand for combination hemostats is growing due to their increased effectiveness in minimizing bleeding complications during complex surgical procedures. Oxidized regenerated cellulose-based hemostats are made from plant-derived cellulose that undergoes oxidation and regeneration processes. They possess antimicrobial properties and effectively control bleeding by creating a physical barrier between blood vessels and surrounding tissues. ORC-based hemostats are often used in dental surgeries, gastrointestinal surgeries, and gynecological procedures. Thrombin-based hemostats contain human or bovine thrombin as their active ingredient, which activates the coagulation cascade, resulting in rapid clot formation. They are particularly useful in controlling bleeding where traditional techniques may be ineffective or impractical, such as cardiovascular surgeries or organ transplantations. The collagen-based hemostats provide excellent biocompatibility and are often preferred for delicate surgeries. Combination hemostats offer increased effectiveness due to their synergistic properties. Gelatin-based hemostats are valued for their rapid blood clotting ability in critical situations. ORC-based hemostats exhibit antimicrobial properties and create a physical barrier for bleeding control, while thrombin-based hemostats activate the coagulation cascade for rapid clot formation.
Formulation: Growing potential of powder hemostats for controlling and preventing bleeding during surgical intervention
Matrix and gel hemostats are biocompatible, absorbable materials that facilitate rapid clot formation. They are preferred in situations where the application of direct pressure during surgery is difficult, such as in minimally invasive procedures. Powder hemostats work by absorbing fluid from bleeding tissue and enhancing platelet aggregation. Their ease of application makes them suitable for various surgical specialties, including general, orthopedic, cardiovascular, and neurosurgery. Sheet and pad hemostats are flexible bioabsorbable materials, allowing for better conformity to irregular wound surfaces. They are utilized in surgeries where larger areas need to be covered, and suturing is challenging. Sponge hemostats are highly absorbent materials easily molded into various shapes, making them suitable for irregular wound cavities. They are commonly used in dental and oral surgeries, as well as neurosurgery and cardiovascular surgery. Matrix & gel hemostats provide rapid clot formation in hard-to-reach areas, whereas powder hemostats offer easy application across surgical specialties. Sheet & pad hemostats conform to irregular wound surfaces covering larger areas; then, sponge hemostats provide excellent absorbency and moldability for irregular wound cavities.
Application: Significant role of hemostats in cardiovascular surgeries to prevent blood loss and ensure successful outcomes
Cardiovascular surgeries involve high blood flow, arteries, and veins, often requiring efficient hemostatic solutions to prevent excessive bleeding. Hemostats are widely preferred in these procedures due to their rapid action and ability to achieve effective hemostasis. In general surgery, the use of hemostats plays a significant role in wound management and ensuring minimum blood loss during procedures such as appendectomy and hernia repair. Gynecological surgeries often require meticulous control of bleeding during delicate procedures such as hysterectomy and myomectomy. Hemostats have effectively minimized adhesions while providing adequate hemostasis during these surgeries. Hemostats are specifically designed to address this need while preserving neural structures. Orthopedic surgeries, including joint replacements and fracture fixation, require robust hemostatic agents as they involve cutting through dense bone and connective tissues. In reconstructive surgery, which includes skin grafting and flap reconstruction, managing blood loss becomes critical for successful outcomes. Hemostatic agents are preferred in these cases due to their adaptability across different tissues and ability to seal large wounds effectively. Compared to other applications, cardiovascular surgeries show a higher need-based preference for advanced hemostatic agents.
Regional Insights
The growing number of surgical procedures with the rising availability of advanced healthcare facilities, especially across the U.S., Canada, and Brazil, are expanding the growth of the hemostats market in the Americas. According to the American Society of Plastic Surgeons, in 2022, a total of 1,017,003 reconstructive surgeries were performed, necessitating the use of hemostats. The emerging trend of medical tourism across Canada, Dubai, Singapore, Japan, and the UK is expanding the number of minimally invasive surgical procedures, thereby creating a platform for the hemostats market. According to the Medical Tourism Index survey (MTA), Canada is one of the preferred destinations, attracting around 14 million Americans from other nations. Ongoing advancements in healthcare infrastructure and technologies across European countries, with constant support from regulatory bodies such as the European Medicines Agency (EMA) on expanding the manufacturing of medical devices and healthcare infrastructure, are bolstering the European market. The Middle East & Africa region presents promising growth opportunities due to increasing healthcare expenditure and government initiatives towards modernizing healthcare infrastructure. Countries, including Saudi Arabia, the United Arab Emirates, and South Africa, are witnessing a surge in the need for effective hemostatic solutions with the rising number of surgical interventions. Moreover, increased government funding to expand the manufacturing of medical devices domestically across India, Australia, China, and Japan and increased awareness associated with minimally invasive surgeries are expected to bolster market growth in Asia-Pacific.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hemostats Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemostats Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hemostats Market, highlighting leading vendors and their innovative profiles. These include A.R. Medicom, Inc., ACTEON Group, Advamedica Inc., Advanced Medical Solutions Group PLC, Advin Health Care, Aegis Lifesciences Private Limited, Argon Medical Devices, B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Betatech Medical, Convatec Group PLC, Cook Group Incorporated, Cortis Medtech Pvt Ltd, Cotran Corporation, Dolphin Sutures by Futura Surgicare Pvt. Ltd., Dynarex Corporation, Gelita AG, Hangzhou Singclean Medical Products Co.,Ltd., Healthium Medtech Ltd, Hemostasis, LLC, Integra LifeSciences Holdings Corporation, Johnson & Johnson Services, Inc., Medcura, Inc., Medline Industries, LP, Medprin Biotech GmbH, Medtronic PLC, Meril Life Sciences Pvt. Ltd., Olympus Corporation, Pfizer Inc., Rousselot BV by Darling Ingredients International Holding B.V., Royal DSM, Shilpa Medicare Limited, Stapleline Medizintechnik GmbH, Stryker Corporation, SYMATESE, Teleflex Incorporated, Terumo Corporation, Zhejiang Perfectseal New Material Technology Co., Ltd., and Zimmer Biomet Holdings, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Hemostats Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemostats Market?
3. What are the technology trends and regulatory frameworks in the Hemostats Market?
4. What is the market share of the leading vendors in the Hemostats Market?
5. Which modes and strategic moves are suitable for entering the Hemostats Market?